These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16133054)
1. Dialysate CA125 levels in children on continuous peritoneal dialysis. Turhan P; Sever L; Caliskan S; Kasapcopur O; Sever A; Hacibekiroglu M; Arisoy N Pediatr Nephrol; 2005 Nov; 20(11):1615-21. PubMed ID: 16133054 [TBL] [Abstract][Full Text] [Related]
2. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis. Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322 [TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability. Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115 [TBL] [Abstract][Full Text] [Related]
4. Dialysate CA125 levels after 5 years on continuous peritoneal dialysis. Candan C; Turhan P; Sever L; Civilibal M; Canpolat N; Caliskan S; Kasapcopur O; Arisoy N Pediatr Nephrol; 2011 May; 26(5):783-8. PubMed ID: 21279389 [TBL] [Abstract][Full Text] [Related]
6. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters. Lai KN; Lai KB; Szeto CC; Ho KK; Poon P; Lam CW; Leung JC Am J Kidney Dis; 1997 May; 29(5):699-705. PubMed ID: 9159303 [TBL] [Abstract][Full Text] [Related]
7. Dialysate CA125 in stable CAPD patients: no relation with transport parameters. Pannekeet MM; Koomen GC; Struijk DG; Krediet RT Clin Nephrol; 1995 Oct; 44(4):248-54. PubMed ID: 8575125 [TBL] [Abstract][Full Text] [Related]
8. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Pannekeet MM; Zemel D; Koomen GC; Struijk DG; Krediet RT Perit Dial Int; 1995; 15(6):217-25. PubMed ID: 7578497 [TBL] [Abstract][Full Text] [Related]
9. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients. Redahan L; Davenport A J Nephrol; 2016 Jun; 29(3):427-434. PubMed ID: 26616639 [TBL] [Abstract][Full Text] [Related]
10. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Krediet RT Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients. Passadakis P; Panagoutsos S; Thodis E; Tsivara I; Sopassi F; Kartali S; Vargemezis V Adv Perit Dial; 1999; 15():40-4. PubMed ID: 10682070 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis. Panorchan K; Davenport A BMC Nephrol; 2014 Sep; 15():149. PubMed ID: 25217152 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport. Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786 [TBL] [Abstract][Full Text] [Related]
14. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031 [TBL] [Abstract][Full Text] [Related]
16. Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. Malik AR; Little MA; Henriksson M; Tam FW; Brown EA J Nephrol; 2007; 20(3):340-9. PubMed ID: 17557268 [TBL] [Abstract][Full Text] [Related]
17. Influence of pH-neutral peritoneal dialysis solution. Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590 [TBL] [Abstract][Full Text] [Related]
18. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688 [TBL] [Abstract][Full Text] [Related]
19. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis. Otsuka Y; Nakayama M; Ikeda M; Sherif AM; Yokoyama K; Yamamoto H; Kawaguchi Y Clin Exp Nephrol; 2005 Dec; 9(4):315-319. PubMed ID: 16362159 [TBL] [Abstract][Full Text] [Related]
20. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis. Sanusi AA; Zweers MM; Weening JJ; de Waart DR; Struijk DG; Krediet RT Perit Dial Int; 2001; 21(5):495-500. PubMed ID: 11757834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]